Abstract: Described herein are compositions and pharmaceutical compositions including poxviruses, in particular vaccinia virus such as modified vaccinia Ankara (MVA) virus, a sulfate salt at a concentration between about 5 mM and 300 mM and a buffer, wherein the composition has a pH of between about 6.0 and 8.5. Also described are methods for stabilizing a poxvirus composition by preparing said viral formulation.

Abstract: Compositions, formulations and kits of combinations of prebiotic and probiotic components are disclosed. The combinations may be useful for enhancing immune system functions and enhancing immune response to cancer in a subject.

Abstract: Disclosed herein are methods of using immunomodulatory sterols as vaccine adjuvants. Accordingly, certain embodiments relates to pharmaceutical compositions containing at least one antigen and at least one immunomodulatory sterol; and, methods of inducing an immunomodulatory response in a patient by administering an immunomodulatory-effective amount of at least one immunomodulatory sterol.

Abstract: The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention.

Abstract: The present disclosure provides methods and compositions for inhibiting the proliferation, differentiation, or development of stem cells and cancer stem cells in a patient in need thereof. The methods involve administering to a patient a therapeutically effective amount of an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. The compositions include an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. Specific antagonists such as antibodies and antisense oligonucleotides, and combination therapy with one or more additional anti-cancer agents, are also provided by this disclosure. Such methods, antagonists, and compositions can be useful, for example, in the treatment of cancer.

Abstract: A method of treating active Systemic Lupus Erythematosus (SLE) in a patient by administering a clinically proven safe and clinically proven effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., the anti-IL-12/IL-23p40 antibody ustekinumab, wherein the patient achieves a significant improvement in disease activity.

Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.

Abstract: The present invention provides a photosensitising composition comprising a mixture of at least one oxygen carrier, at least one oxidising agent and at least one surfactant, and its uses. The ratio of the at least one oxygen carrier to the at least one oxidising agent to the at least one surfactant may be in the range of 50:40:10 to 80:19.8:0.2. The photosensitising composition may be used for treating and/or preventing conditions caused by microorganisms.

Abstract: Compositions and methods are described for delivery of drugs to desired tissues via soluble quantum dots.

Abstract: Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

Abstract: A sterile aqueous formulation of a carbonic anhydrase inhibitor such as brinzolamide in combination with polymers like Soluplus® and a surfactant like polysorbate 80, as well as methods of preparation thereof, is disclosed. The formulation relates to the highly solubilized or an amorphous form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.

Abstract: Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises a soluble corticosteroid and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, or an intra-lesional injection.

Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.

Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.

Abstract: The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.

Abstract: A unit-type polyion complex for use in delivering nucleic acid to a target site in a patient includes one or more molecules of a block copolymer having a poly(ethylene glycol) segment and a cationic poly(amino acid) segment and one or more molecules of a nucleic acid. A total quantity of positive charges derived from side chains of the cationic poly(amino acid) segment of the block copolymer in the unit-type polyion complex is not offset by a total quantity of negative charges derived from the nucleic acid. Furthermore, the nucleic acid has a strand length of 10-50 bases, the molecular weight of the poly(ethylene glycol) segment is 40×103 or more, and the block copolymer has a binding constant (Ka) for the nucleic acid of 3.0×105 or more.

Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.

Abstract: The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

Abstract: Provided are methods and compositions to target delivery of cells to a tissue lesion, thereby treating the lesion. For example, biotinylated antibodies with affinity to a lesion epitope are administered at the lesion. Reparative cells including avidin and biotin are then administered at the lesion. The reparative cells are targeted to the lesion via avidin-biotin bridges to the antibodies, with additional cells recruited to the lesion via cell-to-cell avidin-biotin bridges. In certain examples, antibody-reparative cell complexes are formed by mixing the biotinylated antibodies with the reparative cells including avidin and biotin. The complexes are then administered at the lesion. In other examples, multivalent antibodies are used to target reparative cells to the lesion, such as by binding an epitope at the lesion and an epitope present on the reparative cell. In other examples, the antibodies are chemically linked to a reparative cell or to a nanosome containing a therapeutic agent.

Abstract: Compositions are provided including NK cells that express chimeric antigen receptors (CARs) specific to CD19 and Her2 and a plurality of cell surface-bound multilamellar liposomal vesicles loaded with one or more anti-cancer therapeutics at an effective amount for inhibiting or killing tumor cells without causing toxicity to the NK cells. Methods of using these compositions to treat a subject with tumor are also provided, including administering an effective amount of the CAR-engineered NK cells, where an effective amount of anti-tumor therapeutics are delivered in particles (e.g., crosslinked multilamellar liposomal vesicles) that are bound to the surface of these CAR-engineered NK cells, without causing toxicity to the carrier NK cells.

Abstract: In certain embodiments a platform technology for the facilitating immune therapy in the treatment of cancer is provided. In certain embodiments nanocarriers are provided that facilitate delivery of an IDO inhibitor in conjunction with an inducer of cell death (ICD-inducer). In certain embodiments the IDO inhibitor is conjugated to a component of a lipid bilayer forming a nanovesicle. In still another embodiment, methods and compositions are provided where an ICD-inducing agent (e.g., doxorubicin, oxaliplatin, mitoxantrone etc.) and an IDO pathway inhibitor (e.g., an IDO inhibitor-prodrug) are integrated into a nanocarrier (e.g. a lipid-bilayer (LB)-coated nanoparticle), that allows systemic delivery to orthotopic pancreatic cancer site.

Abstract: The present invention relates to the field of extracellular vesicles. More specifically, the present invention provides methods and compositions for using extracellular vesicles as a vector for nucleic acid treatment in vivo of various diseases. In a specific embodiment, the present invention provides an extracellular vesicle isolated from a cell comprising one or more microRNAs (miRNAs) that have been loaded ex vivo into the vesicle so that the miRNAs are present in a higher concentration than when measured in the same extracellular vesicle isolated directly from the cell. In another embodiment, the present invention provides a method for treating cholangiocarcinoma in a subject comprising the step of administering to the subject a plurality of exosomes comprising miR-195.

Abstract: A porous protocell is provided comprising one or more non-integrating vectors comprising nucleic acid encoding a non-nucleolytic fusion protein comprising a protein sequence that specifically binds a sequence in a double strand nucleic acid molecule linked to a protein sequence that is a transcriptional mediator, and optionally guide RNA or a vector for expression of guide RNA, and methods of using the protocells.

Abstract: Recombinant vectors containing at least: a backbone comprising essential sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi operatively linked to a first expression control element that regulates expression of the nucleic acid encoding the RNAi of the CCR5; a nucleic acid encoding at least the extracellular domain of CD25 operatively linked to a second expression control element that regulates expression of the nucleic acid encoding at least the extracellular domain of CD25 are provided by this disclosure. In an alternative aspect, the vector also contains polynucleotides encoding TRIM5alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.

Abstract: A method for the systemic delivery of a polypeptide within a subject is provided by creating genetically modified skin cells via topical introduction of a genetically engineered virus which delivers a nucleic acid encoding a therapeutic polypeptide for expression by the skin cells, wherein the expressed therapeutic polypeptide is secreted by the skin cells and is introduced into the circulatory system of the subject.

Abstract: The present invention relates to the use of lipid/fat droplet deposits in retinas of a human subject as a biomarker for diagnosing, prognosing, and/or monitoring retinal neurodegeneration with or without an elevated intraocular pressure in glaucoma.

Abstract: Described herein are X-ray imageable polymers such as polymeric particles comprising bismuth as a radiopacifying agent, methods of making the polymers, and methods of using the polymers. The imageable particles may comprise a covalently bound compound which chelates the bismuth, for example, through a combination of nitrogen and oxygen atoms.

Abstract: The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.

Abstract: The invention provides a novel class of MRI contrast agents based on biogenic hemin and compositions and methods of preparation and use thereof.

Abstract: The invention provides a novel class of clearable, tumor-targeting and human protein-based MRI nanoprobes and contrast agents and their compositions, and methods of preparation and use thereof.

Abstract: Provided herein, in some aspects, are methods of administering to a subject a thymidine kinase substrate having a label and detecting presence or absence of the label as an indication of the presence of a polyomavirus (e.g., JCV and BK).

Abstract: The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.

Abstract: The presently disclosed subject matter provides uses of anti-B7H3 antibodies for treating cancers in the central nervous system (CNS), including tumors metastatic to CNS, and in particular leptomeningeal carcinomatosis.

Abstract: Mesothelin (MSLN) has been found to be overexpressed in several human malignancies: 100% of epithelial mesotheliomas, the majority of pancreatic and ovarian adenocarcinomas, more than 50% of lung adenocarcinomas and 34 to 67% of triple negative breast cancer (TNBC). The limited expression of mesothelin in normal human tissues and its overexpression in several aggressive human cancers make MSLN an attractive candidate for therapy. The objective of the inventors was to perform the nuclear imaging of TNBC xenografts with anti-MSLN single domain antibodies radiolabeled with 99mTc (99mTc-A1 and 99mTc-C6). They showed that 99mTc-A1 represent a good candidate for targeting mesothelin positive tumors. Accordingly, the present invention to an anti-mesothelin single domain antibody which is labelled with a radionuclide and its uses for imaging and/or treating cancer.

Abstract: Some embodiments of the present disclosure include a disinfecting/cleaning box for disinfecting and cleaning a virtual reality (VR) visor. The disinfecting/cleaning box may include a box body having an inner volume sufficient to accommodate the visor; a lid attached to the box body; a plurality of vents extending through walls of the box body; an air jet nozzle extending from at least one of the walls towards an interior of the box body; a pressurized air tube attached to the air jet nozzle, the pressurized air tube configured to provide pressurized air to be dispersed through the air jet nozzle toward the interior of the box body; and at least one ultraviolet (UV) light emitting diode (LED) attached to an inner surface of the wall, the UV LED configured to emit UV light toward the interior of the box body.

Abstract: A station for a handheld information device (HID) includes a station body having a periphery and a receiving surface to support at least a portion of the HID. A visible antimicrobial illumination (VAI) emitter is coupled to the station body and arranged to direct a human-visible illumination beam at a target surface of the HID to produce an antimicrobial effect on the target surface. At least a first portion of the target surface is external to the periphery of the station body, and the human-visible illumination beam is projected beyond the periphery to illuminate the first portion of the target surface.

Abstract: Systems, methods, and apparatuses involving lighting device dissipation are provided. An example light emitting device for inactivating microorganisms may comprise a vent configured to allow air to flow therethrough. The light emitting device may comprise a light emitter disposed on a substrate and configured to at least produce a light. The light may comprise a radiant flux sufficient to initiate inactivation of microorganisms, wherein at least 20% of a spectral energy of the light is in a wavelength in a range of 380-420 nanometers (nm). The light emitting device may comprise a fan configured to create an airflow through the vent and towards the substrate.

Abstract: Ultraviolet radiation is directed within an area. The storage area is scanned and monitored for the presence of biological activity within designated zones. Once biological activity is identified, ultraviolet radiation is directed to sterilize and disinfect designated zones within the storage area.

Abstract: The invention discloses a special disinfection cabinet for wooden cutting boards. The disinfection cabinet includes a disinfection cabinet. The disinfection cabinet is provided with a disinfection cavity which is opened forward. The disinfection cavity is provided with a support plate. The cutting board is placed on the left end face of the support plate, the cutting board is clamped by the clamping mechanism, and a pushing mechanism is provided on the right side of the support plate. Before disinfecting the cutting board, the invention first polishes the surface of the cutting board Grind off the surface of the cutting board, so that most mold can be removed, and the knife marks on the surface of the polished cutting board can also be removed to prevent bacteria from accumulating and breeding. Then rinse the cutting board and use ultraviolet radiation to Compared with the traditional disinfection method, the disinfection effect is better.

Abstract: The invention relates to a method for disinfecting soils or other agricultural growing media, characterised by comprising the following steps: obtaining a soil or other agricultural growing medium at their field capacity; treating the soil or medium at the field capacity of the previous step with ozonated water, wherein the ozonated water is prepared in situ with ozone-production equipment connected to the water supply; allowing a period of time to pass after the treatment with ozone; and inoculating the disinfected soil or agricultural medium with at least one species of beneficial microorganism.

Abstract: An ozone distribution system wherein an ozone generator of known type in use supplies ozone at a preselected concentration to an ozone distribution pipe which is arranged to pass through or around the area to be treated with ozone, said ozone distribution pipe being arranged to provide a continuous circuit and to provide a smooth path without sharp bends, said ozone distribution pipe being perforated at intervals along its length, to allow ozone to disperse from the pipe.

Abstract: Provided is a stretchable film having excellent stretchability, excellent air permeability, and an excellent deodorizing property. Also provided is an article including such stretchable film. A stretchable film of the present invention is a film having stretchability, and includes a deodorant. The stretchable film of the present invention is a film having stretchability, and has a deodorization efficiency for each of ammonia and hydrogen sulfide 3 hours after the start of a deodorization test, the deodorization efficiency being measured by a detector tube method, of 10% or more.

Abstract: A USB scent diffuser having a first housing rotatably connected to a second housing. Disposed within the first housing is a first circuit board attached to a USB connector, an on/off button, and an indicator light. Disposed within the second housing is a second heat producing, circuit board and a fragrance emitting member. The first and second housing are connected so that the second housing is rotated in relation to the first housing so that the fragrance emitting member is selectively positioned above the second heat producing circuit board.

Abstract: A method and apparatus for vapor dispensing apparatus is described. The vapor dispensing apparatus includes: a housing defining a chamber having an inner contact surface, wherein the housing further comprises an aperture providing fluid communication between the chamber and an external environment; an evaporable material receptacle movably disposed within the chamber such that a dispensing portion of the receptacle is disposed in contact with at least a portion of the surface; and a motor coupled to the apparatus, configured to move the receptacle.

Abstract: An oil fan diffuser having a housing with a first section and a second section. A power source such as a plurality of batteries are disposed within the second section. Disposed within the first section is a fan, an inner housing, a fragrance emitting member, a retaining member, and an inverted fragrance bottle.

Abstract: A biomaterial that includes collagen and an antimicrobial agent such as citric acid is provided herein. The biomaterial may further include a metal, such as silver, and an anionic polysaccharide, such as oxidized regenerated cellulose (ORC). Methods of using the biomaterial in wound therapy and on medical implants, and methods for preparing the biomaterial are also disclosed herein.

Abstract: Disclosed are natural baby products and related methods of use. Disposable baby hygiene products, particularly disposable baby hygiene products made with natural, sustainable, environmentally-responsible, and/or biodegradable materials include disposable baby diapers made with bamboo and other natural, sustainable, environmentally-responsible, and/or biodegradable materials and disposable baby swim diapers made with natural, sustainable, environmentally-responsible, and/or biodegradable materials.

Abstract: This invention is related to a surgical suture production method that has been given electrical conductivity to the surgical suture. The surgical suture production method subjected to the invention comprises the steps of, dissolving a conductive or semi conductive polymer that is to be used as coating material in a solvent together with a dopant that increases electrical conductivity, immersing the surgical suture inside this solution and coating the suture, taking the suture out of the solution and obtaining an electrical conductive layer on the suture after the solution on it has evaporated.